Animal biotechnology is a branch of biotechnology in which molecular biology techniques are used to genetically engineer (i.e. modify the genome of) animals in order to improve their suitability ...

Biotech incubator Flagship Pioneering has uncorked its latest company. Lila Sciences is looking to use $200 million in seed funding to develop new advanced artificial intelligence that can power ...

Lila was conceived inside Flagship Pioneering, an investor in and prolific creator of biotechnology companies, including the Covid-19 vaccine maker Moderna. Flagship conducts scientific research ...

China has captured production of portions of the global biotechnology supply chain to accomplish President Xi Jinping’s goal to “develop effective deterrent against attempts by other countries ...

And like many other young players in the biotechnology business, this one's also still booking sizable losses, adding to investors' general disinterest. What this company lacks in size and profits ...

In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies from importing goods into China. By Alexandra Stevenson Reporting from ...

First, let’s take a look at the private biotech investments in February 2025, breaking them down by value, location, funding type, and therapeutic subsector. In February 2025, Eikon Therapeutics ...

Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million per target to access technology for the tissue-selective delivery of molecules to cardiometabolic targets inside cells.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology sector regain its footing after a shaky year. No biotech has priced an IPO ...

No sector is left unchanged by the power of AI and digital modeling, and Biotech is no exception. This is because biology is by far the most “messy” of hard sciences. Chemistry or physics can deal ...

No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or ...

True, this mid-cap biotech still looks risky. It has yet to start late-stage studies for any candidate. And like most clinical-stage biotechs, Viking generates no revenue and is unprofitable.